VK2735 in 2026: Viking Therapeutics' Oral & Injectable GLP-1/GIP Dual Agonist — Trial Data, Dosage & Comparisons

VK2735 just finished Phase 3 enrollment on its injectable arm while its oral tablet posted 12.2% weight loss in Phase 2. Here's the VENTURE and VANQUISH trial data, safety signals, and how it stacks up against tirzepatide and retatrutide.